Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ocuphire Pharma, Inc. OCUP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ocuphire Pharma, Inc. (OCUP) is a Biotechnology company in the Healthcare sector, currently trading at $1.17. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Net income is $50M (loss), growing at -206%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $0 against $15M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.43 (strong liquidity). Debt-to-assets is 0%. Total assets: $50M.

Analyst outlook: 5 / 5 analysts rate OCUP as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income ?/100 (Fail).

OCUP SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OCUP

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
OCUP: -76.1%/yr revenue is, -206%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
OCUP: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet OCUP: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.43 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
OCUP: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate OCUP as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.0715-3.3994
Volume675.97K
Avg Volume (30D)139.15K
Market Cap$31.74M
Beta (1Y)0.31
Share Statistics
EPS (TTM)-0.80
Shares Outstanding$622.22M
IPO Date2005-11-10
Employees14
CEOGeorge Magrath
Financial Highlights & Ratios
EBITDA$-38.6M
Net Income$-49.59M
Operating Income$-38.6M
Total Cash$45.09M
Net Debt$-45.09M
Total Assets$50.24M
Price / Earnings (P/E)-1.5
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS67577R1023

Price Chart

Track all markets on TradingView
OCUP
Ocuphire Pharma, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.07 52WK RANGE 3.40

People Also View

KOD
KOD
Kodiak Sciences Inc.
$45.07
+7.44%
 CTIC
CTIC
CTI BioPharma Corp.
$9.10
+0.06%
 EYPT
EYPT
EyePoint Pharmaceuticals, Inc.
$14.34
-1.24%
 SLS
SLS
SELLAS Life Sciences Group, Inc.
$4.86
+2.10%
 RIGL
RIGL
Rigel Pharmaceuticals, Inc.
$31.39
+4.74%
 CKPT
CKPT
Checkpoint Therapeutics, Inc.
$4.26
+0.00%
 PLX
PLX
Protalix BioTherapeutics, Inc.
$2.36
+3.06%
 FBIOP
FBIOP
Fortress Biotech, Inc.
$13.37
-2.33%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message